Efficacy of second CAR-T (CART2) infusion limited by poor CART expansion and antigen modulation
Elizabeth M. Holland(University of Maryland, Baltimore), Nirali N. Shah(National Institutes of Health), John C. Molina, Constance M. Yuan(National Cancer Institute), Terry J. Fry(University of Colorado Anschutz Medical Campus), Bonnie Yates(National Institutes of Health), Maryalice Stetler‐Stevenson(National Cancer Institute), Haneen Shalabi(Center for Cancer Research), David F. Stroncek(Yale University), Kniya DéDé, Ting Zhou(Memorial Sloan Kettering Cancer Center), Daniel Moyer(National Institutes of Health), Lauren Little(Rush University), Crystal L. Mackall(Parker Institute for Cancer Immunotherapy), Hao‐Wei Wang(Fu Jen Catholic University), Sandhya R. Panch(University of Washington), Daniel W Lee(National Cancer Institute), Steven L. Highfill(National Institutes of Health)
Cited by 59
Related Papers
IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion
|Genes & Development|2010|744
CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity
|Nature Communications|2016|435
Programming CAR-T cells to kill cancer
|Nature Biomedical Engineering|2018|435
CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial
|Journal of Clinical Oncology|2020|422